Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 2/20 | 0.41 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 2/20 | 0.35 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.34 |
| ▸ | SGK1 | O00141 | 1/20 | 0.34 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.34 |
| ▸ | CDK1 | P06493 | 2/20 | 0.34 |
| ▸ | FLT3 | P36888 | 2/20 | 0.34 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.34 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12338423 | 1.00 | JAK3 (0.41) | JAK3CAMKK2ACACBPLCG1PDPK1 | |
| SCHEMBL8940203 | 0.90 | NEK1 (0.40) | JAK3PLCG1CDK1FLT3NEK1 | |
| SCHEMBL1038090 | 0.90 | JAK3 (0.39) | JAK3PLCG1CDK1FLT3NEK1 | |
| SCHEMBL8941875 | 0.89 | JAK3 (0.38) | JAK3ACACBBTKPIK3CGSGK1 | |
| SCHEMBL12338421 | 0.89 | JAK3 (0.38) | JAK3ACACBBTKPIK3CGSGK1 | |
| SCHEMBL8941710 | 0.89 | JAK3 (0.39) | JAK3ACACBBTKCDK1FLT3 | |
| SCHEMBL12338413 | 0.89 | JAK3 (0.39) | JAK3ACACBBTKCDK1FLT3 | |
| SCHEMBL8940371 | 0.87 | JAK3 (0.39) | JAK3CAMKK2BTKPIK3CGSGK1 | |
| SCHEMBL8940466 | 0.87 | CDK2 (0.38) | JAK3SGK1CDK1FLT3NEK1 | |
| SCHEMBL8940541 | 0.87 | CYP3A4 (0.40) | JAK3SGK1CDK1FLT3NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152103-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2015-06-04 | — | — | US | disclosed |
| US-20150152103-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2015-06-04 | — | — | US | disclosed |
| US-8987454-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987454-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-03-24 | — | — | US | disclosed |
| US-8722889-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722889-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-05-13 | — | — | US | disclosed |
| US-8501446-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-06 | — | — | US | disclosed |
| US-20120258958-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-11 | — | — | US | disclosed |
| US-8188281-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188281-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-20090176763-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
| US-20090176763-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
| US-7507826-B2 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-03-24 | — | — | US | disclosed |
| US-7507826-B2 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258958-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | JAK3, JAK2, JAK1 | JAK3 1/4885CAMKK2 435/4885ACACB 3366/4885 |
| US-20090176763-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | JAK3, JAK2, JAK1 | JAK3 1/4885CAMKK2 435/4885ACACB 3366/4885 |
| US-20150152103-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | JAK3, JAK2, JAK1 | JAK3 1/4885CAMKK2 435/4885ACACB 3366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.